Report of Foreign Issuer (6-k)
June 30 2017 - 11:09AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the month of June 2017
Commission File Number: 001-36737
NeuroDerm Ltd.
(Translation of registrant’s name
into English)
NeuroDerm Ltd.
Ruhrberg Science Building
3 Pekeris St.
Rehovot 7670212, Israel
+972 (8) 946-2729l
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXPLANATORY NOTE
On June 27, 2017, NeuroDerm Ltd. (the
“
Company
”) issued a press release titled, “Results of NeuroDerm’s ND0612H Phase II Trial Presented
in Oral Session at the 3rd Congress of the European Academy of Neurology.” A copy of this press release is attached to this
Form 6-K as Exhibit 99.1.
The information excluding the second paragraph
of Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K is hereby incorporated by reference in the Company’s
registration statements on Form F-3, SEC file number 333-210496, filed with the SEC on March 31, 2016, and on Form S-8, SEC file
numbers 333-217115, 333-210497, 333-205485 and 333-200331, filed with the SEC on April 3, 2017 March 31, 2016, July 2, 2015 and
November 18, 2014, respectively.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
NeuroDerm Ltd.
|
|
|
|
|
|
Date: June 28, 2017
|
By:
|
/s/ Roy Golan
|
|
|
Name: Roy Golan
Title: Chief Financial Officer
|
Exhibit Index
Exhibit
|
|
Description
|
|
|
|
99.1
|
|
Press release dated June 27, 2017 and titled, “Results of NeuroDerm’s ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology.”
|
NEURODERM LTD. (NASDAQ:NDRM)
Historical Stock Chart
From May 2024 to Jun 2024
NEURODERM LTD. (NASDAQ:NDRM)
Historical Stock Chart
From Jun 2023 to Jun 2024